JP2012502113A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502113A5
JP2012502113A5 JP2011527020A JP2011527020A JP2012502113A5 JP 2012502113 A5 JP2012502113 A5 JP 2012502113A5 JP 2011527020 A JP2011527020 A JP 2011527020A JP 2011527020 A JP2011527020 A JP 2011527020A JP 2012502113 A5 JP2012502113 A5 JP 2012502113A5
Authority
JP
Japan
Prior art keywords
use according
administration
monocytes
antibody
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011527020A
Other languages
English (en)
Japanese (ja)
Other versions
JP5976319B2 (ja
JP2012502113A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/056809 external-priority patent/WO2010030979A2/en
Publication of JP2012502113A publication Critical patent/JP2012502113A/ja
Publication of JP2012502113A5 publication Critical patent/JP2012502113A5/ja
Application granted granted Critical
Publication of JP5976319B2 publication Critical patent/JP5976319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011527020A 2008-09-12 2009-09-14 病原性単球の標的化 Active JP5976319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9656308P 2008-09-12 2008-09-12
US61/096,563 2008-09-12
PCT/US2009/056809 WO2010030979A2 (en) 2008-09-12 2009-09-14 Targeting pathogenic monocytes

Publications (3)

Publication Number Publication Date
JP2012502113A JP2012502113A (ja) 2012-01-26
JP2012502113A5 true JP2012502113A5 (enExample) 2012-10-11
JP5976319B2 JP5976319B2 (ja) 2016-08-23

Family

ID=42005801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527020A Active JP5976319B2 (ja) 2008-09-12 2009-09-14 病原性単球の標的化

Country Status (7)

Country Link
US (2) US8242074B2 (enExample)
EP (1) EP2326347A4 (enExample)
JP (1) JP5976319B2 (enExample)
CN (1) CN102209557A (enExample)
AU (1) AU2009291536B2 (enExample)
CA (1) CA2737056C (enExample)
WO (1) WO2010030979A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101253409A (zh) * 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
WO2007132338A2 (en) * 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
SI2109623T1 (sl) * 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
PL2285409T3 (pl) * 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
ES2703774T3 (es) * 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
AU2015203524B2 (en) * 2010-06-18 2016-10-20 Xbiotech Inc. Arthritis treatment
AU2015271978B2 (en) * 2010-08-23 2017-10-26 Xbiotech Inc. Treatment for neoplastic diseases
NZ607472A (en) * 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
KR102004554B1 (ko) * 2011-04-01 2019-10-01 엑스바이오테크, 인크. 피부과학적 병리의 치료
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
MX356808B (es) 2011-09-23 2018-06-14 Xbiotech Inc Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
JPS6040858A (ja) * 1983-08-15 1985-03-04 Nissan Motor Co Ltd 自動変速機の油圧制御装置
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
HU9803037D0 (en) * 1988-05-27 1999-11-29 Synergen Inc Interleukin-1 inhibitors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
DE69327659T2 (de) 1992-10-14 2000-09-21 Nycomed Imaging As, Oslo Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
MXPA02012867A (es) * 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
WO2003015128A2 (en) * 2001-08-07 2003-02-20 Corporation For National Research Initiatives An electromechanical switch and method of fabrication
AU2002343609B2 (en) * 2001-11-16 2008-12-11 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
CN104178491B (zh) * 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
CN101253409A (zh) 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
WO2007132338A2 (en) * 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
SI2109623T1 (sl) 2006-05-22 2012-05-31 Xbiotech Inc Zdravljenje raka z anti il protitelesi
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
ES2763703T3 (es) 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
PL2285409T3 (pl) 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
CN102369217A (zh) 2009-01-29 2012-03-07 雅培制药有限公司 Il-1结合蛋白

Similar Documents

Publication Publication Date Title
Flossmann et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis
JP2009539841A5 (enExample)
JP2010222367A5 (enExample)
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA200971130A1 (ru) Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
JP2014511863A5 (enExample)
JP2013501814A5 (enExample)
EA201370105A1 (ru) Человеческие антитела против человеческого tnf-подобного лиганда-1а (tl1a)
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
MA38276A1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
JP2014523906A5 (enExample)
JP2010532761A5 (enExample)
PH12013500108A1 (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
NZ599315A (en) Antibody therapeutics with local activity in the digestive tract
HRP20211559T1 (hr) Rnk za liječenje autoimunih bolesti
MX347871B (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
JP2013537539A5 (enExample)
WO2011055980A3 (ko) 산화아연-결합성 펩타이드를 포함하는 단백질과 산화아연 나노입자의 복합체 및 그의 용도
EP2478901A3 (en) Neurogenic compounds
UA114699C2 (uk) Комбінована фармацевтична композиція та методи лікування захворювань або станів, пов'язаних з серцево-судинною системою
WO2007087557A3 (en) Surface-layer protein coated microspheres and uses thereof
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
EA201171352A1 (ru) Антигенсвязывающие фрагменты антитела и их применение для лечения или диагностики глазных болезней